arrow
M

Mariana Bastos-Oreiro

Hospital General Universitario Gregorio Marañon
H指数:20
被引数:1,576

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EZH2 mutation status predicts inferior outcomes after bendamustine-based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study

EZH2突变状态预测滤泡性淋巴瘤一线 bendamustine为基础的免疫化疗后较差的预后:一项GELTAMO多中心验证研究

2026-10-170
OAAI
Correction: Beyond Binary FISH Results: Targeted NGS Provides Deeper Characterization of MYC and Broader Genomic Alterations in DLBCL

更正:超越二进制FISH结果:靶向NGS提供了DLBCL中MYC更深入的表征和更广泛的基因组改变

2026-05-220
PREAI
Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma

Prior Bendamustine Exposure对复发/难治性滤泡性淋巴瘤中双特异性抗体疗效的影响

2026-01-090
OAAI
Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy

大B细胞淋巴瘤患者接受CAR T细胞治疗时的患者选择与治疗结果随时间的变化

2025-09-300
PRE
Camidanlumab Tesirine in Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study

Camidanlumab Tesirine 在复发或难治性经典型霍奇金淋巴瘤中的应用:一项 II 期研究

2025-08-190
OAAI
A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial

一项Ib/II期临床试验,将brentuximab vedotin与环磷酰胺、丙卡巴肼、泼尼松、依托泊苷和米托蒽醌(BrEPEM)联合用于未经治疗的老年经典型霍奇金淋巴瘤患者:一项多中心GELTAMO试验

2025-07-250
PRE
ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling

CD19 car-t治疗中的ICANS风险模型: 来自血清和CSF细胞因子分析的见解

2025-07-240
OAAI
TAFASITAMAB PLUS LENALIDOMIDE AS SALVAGE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD EXPERIENCE FROM GELTAMO

妥英珠单抗联合来那度胺作为弥漫性大B细胞淋巴瘤的挽救治疗:GELTAMO的真实世界经验

2025-07-180
OAAI
Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study

自体干细胞移植治疗复发/难治性大B细胞淋巴瘤:一项多中心GETH-TC/GELTAMO研究

2025-04-030
OA
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy

结外受累的大B细胞淋巴瘤的位点特异性分析揭示了嵌合抗原受体T细胞疗法的独特疗效

LEUKEMIA
IF13.4
2025-04-010
PRE
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

嵌合抗原受体T细胞疗法在T细胞/组织细胞丰富的大B细胞淋巴瘤中的疗效及疾病进展后的后续治疗策略:一项GELTAMO/GETH研究

2025-02-040
OAAI
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
2024-11-070
OAAI
Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

通过肠道微生物组和丁酸盐增强非霍奇金淋巴瘤的CAR-T细胞疗法

BLOOD
IF23.1
2024-11-050
PRE
Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

西班牙套细胞淋巴瘤(MCL)治疗模式与治疗顺序的演变及其对生存的影响:Geltamo-MCL-2022研究

BLOOD
IF23.1
2024-11-050
PRE
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

大b细胞淋巴瘤患者在三线或更晚线治疗car-t进展后CAR预后指数的开发和验证

2024-10-290
OAAI
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO

老年患者的Anti-CD19 car-t细胞治疗: 来自GETH-TC/GELTAMO的多中心真实世界经验

2024-10-012
PRE
Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2024-09-030
OAAI
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
2024-06-260
OAAI
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
2024-05-212
OAAI